Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the completion of the sale, the chief executive officer now directly owns 276,017 shares in the company, valued at $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Saurabh Saha also recently made the following trade(s):
- On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.
- On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total value of $867,350.00.
Centessa Pharmaceuticals Price Performance
CNTA stock opened at $15.75 on Friday. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The stock's fifty day simple moving average is $16.47 and its 200-day simple moving average is $16.38. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $1,609,000. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $777,000. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $4,951,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $4,305,000. Institutional investors and hedge funds own 82.01% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CNTA. Morgan Stanley reissued an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reissued a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $26.00.
View Our Latest Stock Analysis on CNTA
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
